- Home
- FORR vs COYA Comparison
FORR vs COYA Comparison
Compare FORR & COYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FORR | COYA |
|---|---|---|
| Founded | 1983 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 135.7M | 124.8M |
| IPO Year | 1996 | 2022 |
Fundamental Metrics
Financial Performance| Metric | FORR | COYA |
|---|---|---|
| Price | $11.68 | $4.81 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $15.80 |
| AVG Volume (30 Days) | 128.0K | ★ 218.0K |
| Earning Date | 05-06-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $7,945,753.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.25 | $763.10 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 123.57 |
| 52 Week Low | $4.88 | $3.71 |
| 52 Week High | $12.33 | $7.75 |
Technical Indicators
Market Signals| Indicator | FORR | COYA |
|---|---|---|
| Relative Strength Index (RSI) | 71.58 | 49.43 |
| Support Level | $6.78 | $4.45 |
| Resistance Level | N/A | $5.18 |
| Average True Range (ATR) | 0.74 | 0.23 |
| MACD | 0.15 | 0.04 |
| Stochastic Oscillator | 90.58 | 83.82 |
Price Performance
Historical ComparisonAbout FORR Forrester Research Inc.
Forrester Research Inc provides independent research, data, and advisory services. It operates through the following segments: The Research segment develops and delivers research, connect, and analytics products; The consulting segment includes the revenues and the related costs of the company's consulting organization, and the Events segment is engaged in developing and hosting in-person and virtual events.
About COYA Coya Therapeutics Inc.
Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary new therapies to enhance the function of regulatory T cells (Tregs). The company's initial development programs are focused on neurodegenerative, chronic inflammatory, autoimmune, and metabolic diseases with high unmet medical needs.